Media Coverage

Three-fourths of physicians said they believe telemedicine visits limit their ability to determine whether patients are at risk for or are currently misusing prescription drugs, according to a new study. Providers are concerned that substance abuse issues are slipping through the cracks in virtual care, as patients experience more stress and mental illness, according to the 2021 Quest Diagnostics Health Trends report released in November.

With the legalization of recreational marijuana in New York earlier this year, most employers cannot penalize job applicants or employees for marijuana use off-duty. But in states across the country, with labor shortages, changing laws and evolving attitudes, fewer companies are testing for marijuana. The rate at which marijuana was being included in urine drug testing declined 5.2% in the United States between 2015 and 2020, said Barry Sample, senior director of science and technology at Quest Diagnostics, which performs more than 10 million drug tests annually.

Quest Diagnostics, a diagnostics services provider in oncology and genetics, has announced that it will provide clinical laboratory testing using the Ki-67 IHC MIB-1 pharmDx (Dako Omnis) immunohistochemistry companion diagnostic.

The New York City-based startup recently launched a new partnership with Quest Diagnostics and brought on Devon Kennard, an American football linebacker for the Arizona Cardinals of the National Football League (NFL), as an investor in the company.

Quest Diagnostics Inc. has completed the consolidations of its Northeast regional operations into its new, 250,000-square-foot facility at ON3 in Clifton, it announced Tuesday. The Secaucus-based diagnostic testing company said in a news release that the lab will serve more than 40 million people per year in seven states, increasing productivity and capacity. It is capable of more than 300,000 tests per day thanks to extensive automation, the company noted.

Steve Rusckowski, Chairman and CEO of Quest Diagnostics, discusses opening a highly automated diagnostic testing facility in New Jersey.

Meg Tirrell joins The Exchange with Quest Diagnostics CEO Steve Rusckowski to discuss the future of Covid testing. As the flu and cold seasons return, Rusckowski says, he expects more people will turn up to Covid testing when they present symptoms that are similar to those of Covid, the flu and the common cold.

Laboratory testing is the backbone of many clinical decisions. Laboratory stewardship helps ensure testing is used for the right patients when it is truly needed. By Lee Hilborne, MD, MPH, Senior Corporate Medical Director, Quest Diagnostics.

An interview with Steve Rusckowski, chairman, chief executive officer and president of Quest Diagnostics. In 2020 the company launched Quest for Health Equity (Q4HE), an over $100 million initiative focused on addressing inequities in health care that affect underserved populations across the U.S. Quest serves half of the hospitals and one-third of the U.S. population annually. The company provides results for nearly two million tests daily, ranging from routine testing to breakthrough genetic testing.

U.S. health regulators authorized the use of the first artificial-intelligence tool designed to help doctors diagnose prostate cancer. The tool, Paige Prostate from New York startup Paige.AI Inc., analyzes digital scans of prostate biopsy slides and compares them against data sets of cell and tissue patterns previously identified as indicators of tumors. Quest Diagnostics Inc., which operates medical testing labs across the U.S., has tested Paige Prostate at its AmeriPath Inc. pathology unit and plans to use the software across various sites as soon as October, said Kristie Dolan, general manager of Quest’s oncology franchise operation.